Overview

STUDY TO EVALUATE THE EFFECT OF PF-06882961 ON SINGLE DOSE ATORVASTATIN, MEDAZOLAM AND ORALCONTRACEPTIVE PHARMACOKINETICS IN HEALTHY ADULT PARTICIPANTS

Status:
Recruiting

Trial end date:
2022-05-13

Target enrollment:

Participant gender:

Summary

The purpose of this study is to characterize the effect of PF-06882961, administered at 2 steady-state dose levels, on the PK of single doses of atorvastatin (20 mg) or midazolam (5 mg), administered separately, in healthy adult male and female participants (Part A), or an OC in healthy PM female participants (Part B).

Phase:

Phase 1

Details

Lead Sponsor:

Pfizer

Treatments:

Atorvastatin
Estradiol
Ethinyl Estradiol
Levonorgestrel
Midazolam